Filing identity and reporting period
The supplied filing is Rosewind Corporation’s Form 10-K for the fiscal year ended August 31, 2012—not an AYTU Biopharma filing or a calendar 2012 Q4 report. The filing describes Rosewind as a development-stage sailing-school business. This mismatch should be resolved before relying on the summary.
Business context
Rosewind planned to provide offshore sailing instruction aboard one vessel, based in San Francisco Bay at the report date. Tuition was $1,750 per student. The company reported only three students trained since inception, including one in fiscal 2012; two were described as regular paying students in the financial discussion.
Financial results and condition
| Metric | FY ended Aug. 31, 2012 | FY ended Aug. 31, 2011 |
|---|---|---|
| Revenue | $1,750 | $0 |
| Operating expenses | $58,106 | $133,619 |
| Operating loss | $56,356 | $133,619 |
| Interest expense | $3,319 | $3,183 |
| Net loss | $59,675 | $136,802 |
| Basic and diluted loss per share | $(0.01) | $(0.03) |
Gross margin is not separately presented; revenue was immaterial relative to operating expenses. Cash used in operations was $37,849, compared with $64,818 in the prior year. Financing provided $33,965, including $16,753 of related-party loan proceeds and $18,212 from stock issuance; ending cash fell to $109 from $3,993.
At year-end, current assets were $186 and current liabilities were $82,365, resulting in a working-capital deficit of $82,179. Total assets were $12,647 and shareholders’ deficit was $69,718. The balance sheet reports $68,053 of related-party loans payable and $8,469 of accrued related-party interest. The filing reports no gross-margin measure.
Material changes and unusual items
- Net loss narrowed by $77,127 (56%), primarily as general and administrative expenses fell to $30,685 from $84,682 and professional fees fell to $20,081 from $44,687. Management attributed part of the prior-year professional-fee comparison to $22,500 of stock issued for consulting services in 2011.
- Revenue increased from zero to $1,750 after one student voyage. Despite the improvement, cumulative operating revenue since inception was only $3,500, against cumulative losses of $510,886.
- Rosewind issued 121,410 shares for $18,212 cash during fiscal 2012. A subsequent stock subscription for 33,334 shares at $0.15 per share was received November 9, 2012.
- The company obtained a waiver permitting limited commercial activity in U.S. waters associated with Washington, California, Hawaii, Texas, and Florida.
Outlook, risks, and contingencies
Management said the business would need substantially more student bookings and additional financing to sustain operations. Its model estimated positive quarterly cash flow only if it sold and completed six one-week voyages per quarter, with two students per voyage. Management said bookings and annual profitability could not be predicted, and no assurance was given that funding or sufficient revenue would be obtained.
The auditor’s report included a going-concern emphasis, citing significant losses and substantial doubt about the company’s ability to continue. Management intended to seek additional equity funding, with no assurance of success. Other risks include very limited demand and marketing results, vessel maintenance needs, weather and seasonality, licensing requirements, dependence on the sole officer/director, and limited insurance. The filing says the vessel itself was uninsured; liability coverage was $100,000 for watercraft liability and $1,000 per person for medical payments. No litigation or regulatory proceeding was reported as pending or threatened.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the supplied text identifies Rosewind Corporation, not AYTU Biopharma, Inc.
- Reconcile the related-party debt disclosures: the balance sheet and Note 2 report $68,053 outstanding, while Item 13 describes a $52,300 secured note and also gives inconsistent maturity information.
- Review the auditor’s going-concern warning, the $109 year-end cash balance, and the company’s ability to raise additional funds.
- Verify the subsequent share subscription and whether it was completed and recorded after year-end.
- Assess the regulatory waiver’s scope, operating limitations, and adequacy of insurance for commercial voyages.